This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
LuPSMA is a randomized phase 2 treatment trial evaluating whether a flexible dosing schedule of 177Lu-PSMA-617 can be compared with the standard fixed dosing schedule in patients with metastatic castration-resistant prostate cancer.
| Feature | LuPSMA |
|---|---|
| NCT ID | NCT06216249 |
| Title | Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) |
| Status | RECRUITING |
| Start date | 2024-08-01 |
| Primary completion date | 2027-12-31 |
| Lead sponsor | Jonsson Comprehensive Cancer Center |
| Allocation | RANDOMIZED |
| Design model | PARALLEL |
| Masking | NONE |
2. Clinical Question
Population
Patients with prostate carcinoma and Stage IVB prostate cancer according to AJCC v8.
Intervention
177Lu-prostate-specific membrane antigen (PSMA)-617 therapy on a flexible dosing schedule.
Comparator
Standard fixed dosing schedule of maximum 6 treatment cycles every 6 weeks.
Primary question
How does survival at 2 years compare between flexible and standard dosing schedules?
3. Trial Design
90 patients
Parallel design
177Lu-PSMA-617
2-year survival
4. Endpoints
| Endpoint | Definition |
|---|---|
| 2-year survival rate | From the date of the first cycle of Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) therapy, up to 2 years. |
The registry describes the primary endpoint as the number and percentage of patients dead 24 months after the first cycle. The endpoint compares patients treated with the flexible dosing schedule with patients treated with the standard fixed dosing schedule.
5. Planned Analysis
Primary endpoint analysis
The registry states that the 2-year survival rate will be reported using descriptive statistics by means of number and percentage of patients dead 24 months after the first cycle.
The ClinicalTrials.gov record does not report posted results for this endpoint.
6. Statistical Methodology
Descriptive survival reporting
The primary endpoint is expressed as a survival rate at a defined time point. A time-point survival measure summarizes the proportion of patients who remain alive at a specified follow-up time rather than estimating the entire survival curve.
This type of endpoint focuses on a clinically defined landmark rather than a relative hazard estimate.
Randomized comparison
Randomization creates the framework for comparing treatment schedules while reducing systematic differences between groups at baseline. Because this trial has two parallel arms and no masking, interpretation must consider the open-label design.
7. Statistical Methods Explained
Why use a randomized design?
Randomization allows investigators to compare dosing strategies while reducing the impact of measured and unmeasured baseline differences.
What does a 2-year survival rate measure?
It measures the proportion of patients alive at a prespecified time point after treatment initiation. It does not describe the timing of events before or after that point.
Why report number and percentage of patients?
A descriptive count and percentage provide a direct summary of the observed landmark outcome.
How is this different from a hazard ratio?
A hazard ratio compares event rates over follow-up using a model-based approach, while a survival rate at 2 years summarizes status at a single time point.
Why does follow-up duration matter?
A landmark survival estimate depends on observing patients long enough to assess the prespecified time point.
8. Limitations
- No posted efficacy results: The ClinicalTrials.gov record does not currently report primary endpoint results.
- Open-label design: Masking is listed as none, which may affect some aspects of trial conduct and assessment.
- Single landmark endpoint: A 2-year survival rate does not fully describe the shape of the survival curve.
- Phase 2 design: Phase 2 trials are generally designed to evaluate treatment approaches before larger confirmatory studies.
- Future data maturity: The primary completion date is listed as 2027-12-31.
9. Why This Trial Matters Statistically
LuPSMA provides a useful example of how randomized oncology trials can compare treatment schedules rather than entirely different therapies. The statistical focus is on whether a flexible dosing strategy can be evaluated using a prespecified survival landmark.
| Concept | How it appears in LuPSMA |
|---|---|
| Randomization | Patients are assigned in a randomized parallel design. |
| Landmark endpoint | Primary endpoint is survival at 2 years. |
| Descriptive statistics | Primary endpoint reported using number and percentage of patients dead at 24 months. |
| Open-label design | Masking is listed as none. |
| Phase 2 evaluation | Trial evaluates a flexible dosing approach. |